CMPX   $5.15  -4.45% Market Closed After Close 5.1613 0.22%

Compass Therapeutics, Inc.
Last Events:

2023-08-06 Signal in MACD changed from bullish reversal to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-05 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-04 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-08-03 Signal in RSI changed from bullish to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-03 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-02 Trend pattern changed from сужающийся канал to расходящийся клин с наклоном вниз.

2023-08-02 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.


Current temperature: 3.34
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 14
Target Price Mean 13.50
Mean unverified/preliminary 13.50 / 13.50
Target Price Low / High 8.00 / 30.00
Median / STD DEV 12.00 / 6.16
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None None ActivelyBuy
rsi Sell Sell ActivelyBuy
macd None None None
stoch None None None
ma20 ActivelyBuy None None
ma50 None None None
ma100 None Buy ActivelyBuy
Candlestick PatternMarch 5, 2026 Long Legged - consists of a Doji with very long upper and lower shadows. Indicates strong forces balanced in opposition.
ISIN US20454B1044
ceo Dr. Thomas J. Schuetz M.D., Ph.D.
Website https://www.compasstherapeutics.com
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.